ArticleDiscover oncology2026
Cuproptosis as a novel predictor of immunotherapy response and shapes the immune landscape in pan-cancer analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The heterogeneity of cancer renders its response to immunotherapy elusive, warranting the identification of robust biomarkers for evaluation. As a form of recently defined regulated cell death (RCD), cuproptosis is driven by copper-dependent proteotoxic stress in mitochondria tricarboxylic acid cycle (TCA cycle), exerting a sophisticated role in antitumor immunity, yet remains poorly understood. Here, we established a cuproptosis score to characterize the immune landscape across 23 human cancers and established the correlation of cuproptosis score with patient immunotherapy outcomes through multi-omics analysis. Bulk and single-cell transcriptomic analysis revealed that with cuproptosis-low patients tend to have improved immunotherapy outcomes compared to those with high cuproptosis scores, with increased immune infiltration and function, as well as abundant cytokines, checkpoints and major histocompatibility complex (MHC) molecules expression. Spatial transcriptomic analysis indicated that immune cells exhibited higher cuproptosis scores than tumor cells, hinting that immune cells are vulnerable to cuproptosis. Further metabolomic and transcriptomic analysis of underlying intrinsic features revealed that cuproptosis-low tumors exhibited a metabolic and signaling pathway profile enrichment favoring antitumor immunity and potent immunogenicity. Overall, our multi-omics analysis suggests cuproptosis score as a robust biomarker for immunotherapy benefit in multiple cancers, reveals cuproptosis-related extrinsic and intrinsic immune landscapes, and provides a broad framework for understanding the relevance of cuproptosis to cancer immunology and clinical benefits of immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.